MolMed SpA (MLM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

MolMed SpA (MLM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH137587D
  • |
  • Pages: 62
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

MolMed SpA (Molmed) is a biotechnology company which offers research, development, manufacturing and clinical validation of novel anticancer therapies. Its pipeline antitumour products include Zalmoxis (TK), a cell based therapy enabling bone marrow transplants donors for the treatment of high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis, inducing a rapid immune reconstitution; NGR-hTNF, a therapeutic agent showing anti-tumor activity for solid tumors; and CAR-CD44v6, an immuno-gene therapy project for haematological malignancies and several epithelial tumours. The company also conducts cell and gene therapy projects such as development and the validation of the manufacturing process and control strategy, cGMP production of clinical-grade viral vectors and manufacturing of patient-specific genetically engineered cells. Molmed is headquartered in Milano, Italy.

MolMed SpA (MLM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MolMed SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MolMed SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MolMed SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

MolMed SpA, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

MolMed Acquires CAR-CD44v6 Project from San Raffaele Hospital 11

Partnerships 12

MolMed Enters into Development Agreement with GlaxoSmithKline 12

MolMed and AbCheck Enter into Agreement 13

Orchard Therapeutics and MolMed Expand Collaboration Agreement 14

MolMed and Cellectis Enter into Co-Development Agreement 15

MolMed Enters into Agreement with Rocket Pharma 16

MolMed Enters into Co-Development Agreement with Genenta Science 17

MolMed Enters into Agreement with GlaxoSmithKline 18

Licensing Agreements 19

MolMed and Dompe Expand Licensing and Distribution Agreement 19

TTY Biopharm Enters into Licensing Agreement with MolMed 20

Megapharm Enters into Licensing Agreement with MolMed for Zalmoxis 21

Oxford BioMedica Enters into Licensing Agreement with MolMed 22

Equity Offering 23

Molmed Raises USD3.6 Million in Fifth Tranche of Private Placement of Shares 23

MolMed Raises USD6.2 Million in Fourth Tranche of Private Placement of Shares 25

MolMed Raises USD2.2 Million in Second Tranche of Private Placement of Shares 27

MolMed SpA-Key Competitors 28

MolMed SpA-Key Employees 29

MolMed SpA-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Jul 30, 2018: MolMed approves results at June 30th 2018 31

May 11, 2018: MolMed approves first quarter 2018 results, significantly improved compared to the first quarter 2017 33

Apr 12, 2018: MolMed: the Shareholders' Meeting approves 2017 Financial Statements 35

Mar 09, 2018: MolMed: Full Year 2017 Results 36

Nov 06, 2017: The Board of Directors Examined the Business Performance and Approved the First Nine Months Financial Report at September 30th, 2017 39

Nov 06, 2017: MolMed Board of Directors examined the business performance and approved the first nine months financial report ended at September 30th, 2017 43

Jul 27, 2017: MolMed Board of Directors reviewed business performance and approved the first half-year financial report ended June 30th, 2017 47

May 08, 2017: MolMed's Board of Directors reviewed business performance and approved Interim Results at March 31st, 2017 51

Mar 06, 2017: MolMed's Board of Directors reviewed the business performance and approved the draft financial statements for FY 2016 53

Corporate Communications 57

Sep 24, 2018: MolMed: Carlo Incerti succeeds to Claudio Bordignon as chairman of the board. Salvatore Calabrese appointed officer responsible for the preparation of corporate financial reports 57

Sep 11, 2018: MolMed names Mr. Salvatore Calabrese Chief Financial Officer 59

Jun 29, 2018: MolMed: resignation of the Officer Responsible for the preparation of corporate financial reports 60

Product Approvals 61

Jun 01, 2017: MolMed provides update on Zafiride Conditional Marketing Authorization application 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62

List of Figures

MolMed SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

MolMed SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MolMed SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MolMed SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

MolMed SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

MolMed SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MolMed SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MolMed SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MolMed SpA, Deals By Therapy Area, 2012 to YTD 2018 9

MolMed SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

MolMed Acquires CAR-CD44v6 Project from San Raffaele Hospital 11

MolMed Enters into Development Agreement with GlaxoSmithKline 12

MolMed and AbCheck Enter into Agreement 13

Orchard Therapeutics and MolMed Expand Collaboration Agreement 14

MolMed and Cellectis Enter into Co-Development Agreement 15

MolMed Enters into Agreement with Rocket Pharma 16

MolMed Enters into Co-Development Agreement with Genenta Science 17

MolMed Enters into Agreement with GlaxoSmithKline 18

MolMed and Dompe Expand Licensing and Distribution Agreement 19

TTY Biopharm Enters into Licensing Agreement with MolMed 20

Megapharm Enters into Licensing Agreement with MolMed for Zalmoxis 21

Oxford BioMedica Enters into Licensing Agreement with MolMed 22

Molmed Raises USD3.6 Million in Fifth Tranche of Private Placement of Shares 23

MolMed Raises USD6.2 Million in Fourth Tranche of Private Placement of Shares 25

MolMed Raises USD2.2 Million in Second Tranche of Private Placement of Shares 27

MolMed SpA, Key Competitors 28

MolMed SpA, Key Employees 29

MolMed SpA, Other Locations 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

MolMed SpA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17743
Site License
USD 500 INR 35485
Corporate User License
USD 750 INR 53228

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com